Form 4: Cumberland Pharmaceuticals Director Kenneth Krogulski Increases Stake Through 10b5-1 Trading Plan

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Kenneth Krogulski, a director of Cumberland Pharmaceuticals, has been acquiring shares of the company's common stock.
• These purchases are being made automatically under a Rule 10b5-1 trading plan that was adopted on March 13, 2024.
• The transactions occurred on multiple dates between June 13, 2024, and June 28, 2024.
• The number of shares acquired per transaction ranged from 134 to 256.
• The prices paid per share ranged from $1.49 to $1.59.
• Following these transactions, Krogulski's direct ownership has increased from 241,411 to 243,557 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The director's stock purchases indicate confidence, but the purchases are part of a pre-arranged plan, so the impact is somewhat muted.

Positives

• The director's consistent purchases may signal confidence in the company's future prospects.
• The use of a 10b5-1 trading plan ensures that the purchases are not based on insider information.

Industry Context

Directors purchasing shares in their own companies is generally viewed positively by the market, as it can signal confidence in the company's prospects. The use of a pre-arranged 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The director's stock purchases could positively influence shareholder sentiment.

Key Dates